Anti-spike IgG causes severe acute lung injury by skewing macrophage responses during acute SARS-CoV infection.

Newly emerging viruses, such as severe acute respiratory syndrome coronavirus (SARS-CoV), Middle Eastern respiratory syndrome CoVs (MERS-CoV), and H7N9, cause fatal acute lung injury (ALI) by driving hypercytokinemia and aggressive inflammation through mechanisms that remain elusive. In SARS-CoV/macaque models, we determined that anti-spike IgG (S-IgG), in productively infected lungs, causes severe ALI by skewing inflammation-resolving response. Alveolar macrophages underwent functional polarization in acutely infected macaques, demonstrating simultaneously both proinflammatory and wound-healing characteristics. The presence of S-IgG prior to viral clearance, however, abrogated wound-healing responses and promoted MCP1 and IL-8 production and proinflammatory monocyte/macrophage recruitment and accumulation. Critically, patients who eventually died of SARS (hereafter referred to as deceased patients) displayed similarly accumulated pulmonary proinflammatory, absence of wound-healing macrophages, and faster neutralizing antibody responses. Their sera enhanced SARS-CoV-induced MCP1 and IL-8 production by human monocyte-derived wound-healing macrophages, whereas blockade of FcγR reduced such effects. Our findings reveal a mechanism responsible for virus-mediated ALI, define a pathological consequence of viral specific antibody response, and provide a potential target for treatment of SARS-CoV or other virus-mediated lung injury.

[1]  R. Couch,et al.  Immunization with SARS Coronavirus Vaccines Leads to Pulmonary Immunopathology on Challenge with the SARS Virus , 2012, PloS one.

[2]  Jincun Zhao,et al.  Virus-Specific Memory CD8 T Cells Provide Substantial Protection from Lethal Severe Acute Respiratory Syndrome Coronavirus Infection , 2014, Journal of Virology.

[3]  Y. Zhang,et al.  Immunogenicity and protective efficacy in monkeys of purified inactivated Vero-cell SARS vaccine , 2005, Vaccine.

[4]  T. Wynn,et al.  Macrophages in Tissue Repair, Regeneration, and Fibrosis. , 2016, Immunity.

[5]  S. Morikawa,et al.  Effects of Toll-Like Receptor Stimulation on Eosinophilic Infiltration in Lungs of BALB/c Mice Immunized with UV-Inactivated Severe Acute Respiratory Syndrome-Related Coronavirus Vaccine , 2014, Journal of Virology.

[6]  K. To,et al.  High Titer and Avidity of Nonneutralizing Antibodies against Influenza Vaccine Antigen Are Associated with Severe Influenza , 2012, Clinical and Vaccine Immunology.

[7]  J. Sung,et al.  Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients , 2004, Clinical Microbiology and Infection.

[8]  J. Edwards,et al.  Exploring the full spectrum of macrophage activation , 2008, Nature Reviews Immunology.

[9]  J. Tregoning,et al.  Immune Responses and Disease Enhancement during Respiratory Syncytial Virus Infection , 2005, Clinical Microbiology Reviews.

[10]  Y. Guan,et al.  Confronting SARS: a view from Hong Kong. , 2004, Philosophical transactions of the Royal Society of London. Series B, Biological sciences.

[11]  N. Petrovsky,et al.  Severe Acute Respiratory Syndrome-Associated Coronavirus Vaccines Formulated with Delta Inulin Adjuvants Provide Enhanced Protection while Ameliorating Lung Eosinophilic Immunopathology , 2014, Journal of Virology.

[12]  M. Kuroda,et al.  In Vivo Characterization of Alveolar and Interstitial Lung Macrophages in Rhesus Macaques: Implications for Understanding Lung Disease in Humans , 2014, The Journal of Immunology.

[13]  S. Goerdt,et al.  Macrophage activation and polarization: nomenclature and experimental guidelines. , 2014, Immunity.

[14]  Taeg S. Kim,et al.  Regulating the adaptive immune response to respiratory virus infection , 2012, Nature Reviews Immunology.

[15]  A. Lackner,et al.  Recently infiltrating MAC387(+) monocytes/macrophages a third macrophage population involved in SIV and HIV encephalitic lesion formation. , 2011, The American journal of pathology.

[16]  L. Wen,et al.  Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys , 2005, Vaccine.

[17]  Jing Xie,et al.  Immunodominant SARS Coronavirus Epitopes in Humans Elicited both Enhancing and Neutralizing Effects on Infection in Non-human Primates , 2016, ACS infectious diseases.

[18]  W. Marasco,et al.  An animal model of SARS produced by infection of Macaca mulatta with SARS coronavirus , 2005, The Journal of pathology.

[19]  T. Wynn,et al.  Protective and pathogenic functions of macrophage subsets , 2011, Nature Reviews Immunology.

[20]  K. Yuen,et al.  Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection against SARS-CoV Infection1 , 2008, The Journal of Immunology.

[21]  F. Polack,et al.  Severe pandemic 2009 H1N1 influenza disease due to pathogenic immune complexes , 2010, Nature Medicine.

[22]  S. Perlman,et al.  Complete Protection against Severe Acute Respiratory Syndrome Coronavirus-Mediated Lethal Respiratory Disease in Aged Mice by Immunization with a Mouse-Adapted Virus Lacking E Protein , 2013, Journal of Virology.

[23]  W. Lim,et al.  The Effectiveness of Convalescent Plasma and Hyperimmune Immunoglobulin for the Treatment of Severe Acute Respiratory Infections of Viral Etiology: A Systematic Review and Exploratory Meta-analysis , 2014, The Journal of infectious diseases.

[24]  K. Yuen,et al.  Priming with rAAV encoding RBD of SARS-CoV S protein and boosting with RBD-specific peptides for T cell epitopes elevated humoral and cellular immune responses against SARS-CoV infection , 2008, Vaccine.

[25]  Yan Guo,et al.  Receptor-binding domain of SARS-CoV spike protein induces long-term protective immunity in an animal model , 2006, Vaccine.

[26]  Lisa E. Gralinski,et al.  A Double-Inactivated Severe Acute Respiratory Syndrome Coronavirus Vaccine Provides Incomplete Protection in Mice and Induces Increased Eosinophilic Proinflammatory Pulmonary Response upon Challenge , 2011, Journal of Virology.

[27]  M. Matthay,et al.  The acute respiratory distress syndrome. , 1996, The New England journal of medicine.

[28]  N. Zhong,et al.  Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque , 2005, Nature Medicine.

[29]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[30]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[31]  M. Peiris,et al.  SARS: clinical virology and pathogenesis , 2003, Respirology.

[32]  D. Ho,et al.  Antibody responses against SARS coronavirus are correlated with disease outcome of infected individuals , 2005, Journal of medical virology.

[33]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[34]  M. Neurath,et al.  Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: Evidence in Crohn disease and experimental colitis in vivo , 2000, Nature Medicine.

[35]  M. Schilham,et al.  Macrophages inhibit human osteosarcoma cell growth after activation with the bacterial cell wall derivative liposomal muramyl tripeptide in combination with interferon-γ , 2014, Journal of experimental & clinical cancer research : CR.

[36]  U. Parashar,et al.  Severe Acute Respiratory Syndrome in Children , 2007, The Pediatric infectious disease journal.

[37]  S. Asa,et al.  Pulmonary pathology of severe acute respiratory syndrome in Toronto , 2005, Modern Pathology.

[38]  K. Mayer,et al.  Acute Lung Injury: How Macrophages Orchestrate Resolution of Inflammation and Tissue Repair , 2011, Front. Immun..

[39]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[40]  R. Baric,et al.  Airway Memory CD4+ T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses , 2016, Immunity.

[41]  David K. Meyerholz,et al.  Dysregulated Type I Interferon and Inflammatory Monocyte-Macrophage Responses Cause Lethal Pneumonia in SARS-CoV-Infected Mice , 2016, Cell Host & Microbe.

[42]  D. Ho,et al.  Recombinant Modified Vaccinia Virus Ankara Expressing the Spike Glycoprotein of Severe Acute Respiratory Syndrome Coronavirus Induces Protective Neutralizing Antibodies Primarily Targeting the Receptor Binding Region , 2005, Journal of Virology.

[43]  P. Chan,et al.  Use of convalescent plasma therapy in SARS patients in Hong Kong , 2004, European Journal of Clinical Microbiology and Infectious Diseases.

[44]  Zhiwei Chen,et al.  Monoclonal antibodies specific to human Δ42PD1: A novel immunoregulator potentially involved in HIV-1 and tumor pathogenesis , 2015, mAbs.

[45]  Arthur S Slutsky,et al.  Identification of Oxidative Stress and Toll-like Receptor 4 Signaling as a Key Pathway of Acute Lung Injury , 2008, Cell.

[46]  K. Harrod,et al.  Primary Severe Acute Respiratory Syndrome Coronavirus Infection Limits Replication but Not Lung Inflammation upon Homologous Rechallenge , 2012, Journal of Virology.

[47]  S. Perlman,et al.  Immunopathogenesis of coronavirus infections: implications for SARS , 2005, Nature Reviews Immunology.

[48]  D. Ho,et al.  Single Amino Acid Substitutions in the Severe Acute Respiratory Syndrome Coronavirus Spike Glycoprotein Determine Viral Entry and Immunogenicity of a Major Neutralizing Domain , 2005, Journal of Virology.

[49]  Zhiwei Chen,et al.  Spatiotemporal interplay of severe acute respiratory syndrome coronavirus and respiratory mucosal cells drives viral dissemination in rhesus macaques , 2015, Mucosal Immunology.

[50]  M. Barry,et al.  The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1. , 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[51]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[52]  Michelle M. Packard,et al.  Prior Infection and Passive Transfer of Neutralizing Antibody Prevent Replication of Severe Acute Respiratory Syndrome Coronavirus in the Respiratory Tract of Mice , 2004, Journal of Virology.